Angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme inhibitors has been studied in 197 papers since 2004: 7 trials and 128 observational studies in people, 1 in animals, 58 reviews; 81 in the past year. The newest paper, Nov 19, 2026: “Cardiovascular Medications as Disease Modifiers for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Literature Review”.
28 new papers in 30 daysSee all 197 papers on angiotensin-converting enzyme inhibitors
At a glance
Independent labs found the same change in people. 43 independent labs in 21 countries.
“The ACEi group reduced the upper body strength, upper and lower body flexibility and aerobic endurance (p<0.05)”
8 of its findings point the other way.
- 43 independent labs in 21 countries
- 8 findings against
- Funders: National Institutes of Health and others
- 8 of 62 findings with company ties
- Human trial7
- Humans128
- Animals1
- In silico2
Studies in people
3 studies gave angiotensin-converting enzyme inhibitors to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases systolic blood pressuremean decrease of 16.4+/- 3.2 mmHg up: Increases eGFRmean increase of 5.6+/- 1.8 mL/min/1.73 m 2 | Randomized trial12 weeks | 120 peopleStage 1 hypertension | Journal of pharmacy & bioallied sciences, Dec 17, 2025 |
no change: Has no effect on mortality no change: Has no effect on cardiovascular disease | Treated cohortin-trial [4.1-year]+post-trial [6.9-year] | 648 peopleolderOlder adults; in older patients with lipid-lowering therapy free of CVD | Heart & lung : the journal of critical care, Oct 29, 2021 |
down: Impairs physical functionp<0.05 up: Increases systolic blood pressurep<0.001 | Trial2 years | 418 peopleolder adultsOlder adults; hypertension with comorbidities | Experimental gerontology, Jun 21, 2017 |
What did studies of angiotensin-converting enzyme inhibitors find?
34Studies of angiotensin-converting enzyme inhibitors measured 34 outcomes; the most studied are cognitive decline (3 studies), handgrip strength (2) and age-related macular degeneration (2).
Cognitive decline
downin humans2downin reviews1
3 studies
Cognitive decline
downin humans2downin reviews1
Angiotensin-converting enzyme inhibitors are linked with lower cognitive decline in humans.
“Angiotensin-converting enzyme inhibitors and metformin were associated with a slower cognitive decline.”
Humans
Cardiometabolic medication exposures and cognitive outcomes in Alzheimer's disease
Age and ageing
Angiotensin-converting enzyme inhibitors are linked with lower cognitive decline in humans among participants without HTN, compared to non-RAS use.
“Among participants without HTN, ACEI use was associated with significantly reduced cognitive decline compared to non-RAS use.”
Humansamong participants without HTN, compared to non-RAS use9 years
A comparison of drugs targeting the renin-angiotensin system and global cognition in aging
Journal of Alzheimer's disease : JAD
Angiotensin-converting enzyme inhibitors protect against cognitive decline (reported as potential benefit in some research; other studies inconsistent).
“While some research highlights the potential benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, other studies show inconsistent results”
Reviewreported as potential benefit in some research; other studies inconsistent
Association of Hypertension with Different Cognitive Disorders
Journal of clinical medicine
Handgrip strength
upin humans1downin humans1
2 studies
Handgrip strength
upin humans1downin humans1
Angiotensin-converting enzyme inhibitors are linked with better handgrip strength in humans (congestive heart failure) (P < .001).
“patients on ACEi demonstrated significantly better HGS and GS compared to non-ACEi patients (P < .001).”
Humanscongestive heart failure
British journal of clinical pharmacology
Angiotensin-converting enzyme inhibitors are linked with lower handgrip strength in humans (linear regression models).
“Statins, ACE-inhibitors, ARBs, diuretics, calcium channel blockers, and sulfonylureas showed a consistent and significant decrease in grip strength in linear regression models.”
Humanslinear regression models
Association Between Reduced Handgrip Strength and Commonly Prescribed Medications
medRxivPreprint
Age-related macular degeneration
no changein humans2HR 1.07
2 studies
Age-related macular degeneration
no changein humans2HR 1.07
Angiotensin-converting enzyme inhibitors were not clearly linked with age-related macular degeneration in humans (hypertension) (adjusted HR 1.07 (95% CI 0.90-1.27) weighted; 0.87 (95% CI 0.71-1.07) matched).
“There was no association of ACE-I use on the risk of AMD compared to CCB use in either the propensity score weighted or matched, on-treatment analysis”
Humanshypertensionmedian follow-up of 2 yearsn = 53,832
British journal of clinical pharmacology
Angiotensin-converting enzyme inhibitors were not clearly linked with age-related macular degeneration in humans (OR 0.90 (95% CI 0.61-1.34)).
“The ORs (95% CI) for AMD occurrence in users prescribed with statins, metformin, ACE inhibitors, and ARBs were 1.12 (0.94-1.32), 1.15 (0.91-1.45), 0.90 (0.61-1.34), and 1.21 (1.05-1.39), respectively.”
Humansin cohorts with diabetes mellitus or cardiovascular disease; exposure within one year before index daten = 2,330
Yonsei medical journal
Mortality
no changein humans1downin humans1
2 studies
Mortality
no changein humans1downin humans1
Angiotensin-converting enzyme inhibitors were not clearly linked with mortality in older patients with lipid-lowering therapy free of CVD.
“There were no significant differences between the two groups for the primary endpoints over the in-trial plus post-trial follow-up”
Humansin older patients with lipid-lowering therapy free of CVDin-trial [4.1-year]+post-trial [6.9-year]n = 648
Heart & lung : the journal of critical care
Angiotensin-converting enzyme inhibitors decrease mortality in humans (heart failure).
“drugs such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers has meant a great step forward in the treatment of patients with this condition that significantly has decreased mortality and morbidity.”
Reviewheart failure
Physical training in chronic heart failure: pathophysiology and clinical evolution
Medwave
Dementia
no changein humans1
1 study
Dementia
no changein humans1
Angiotensin-converting enzyme inhibitors were not clearly linked with dementia in humans (compared with angiotensin II receptor blockers).
“There was no significant difference in dementia risk between initiators of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).”
Humanscompared with angiotensin II receptor blockers
RAS inhibitors linked to lower dementia risk than CCBs
Drugs & aging
CD31+ CXCR4+ Th and Treg cell preservation
upin humans1
1 study
CD31+ CXCR4+ Th and Treg cell preservation
upin humans1
Angiotensin-converting enzyme inhibitors are linked with higher CD31+ CXCR4+ Th and Treg cell preservation in humans (Arterial hypertension).
“Therapy with ACEI prevented also loss of CD31 + CXCR4+ Th and CD31 + CXCR4+ Treg cells”
HumansArterial hypertension
Scientific reports
Serum lymphangiogenic potential
upin humans1
1 study
Serum lymphangiogenic potential
upin humans1
Angiotensin-converting enzyme inhibitors are linked with higher serum lymphangiogenic potential in humans (Recently diagnosed arterial hypertension; serum activity evaluated in an animal model).
“Two years after treatment implementation, the lymphangiogenic potential of the patients' sera was restored only in patients treated with angiotensin converting enzyme inhibitors (ACEI).”
HumansRecently diagnosed arterial hypertension; serum activity evaluated in an animal model2 years
Scientific reports
Chronic kidney disease
downin humans1
1 study
Chronic kidney disease
downin humans1
Angiotensin-converting enzyme inhibitors protect against chronic kidney disease in patients with stage 3 to 5 chronic kidney disease.
“in patients with stage 3 to 5 chronic kidney disease, limited evidence suggests that ACEIs may confer superior renoprotective benefits.”
Reviewin patients with stage 3 to 5 chronic kidney disease
All in on ARBs: Is it time to fold the ACEIs?
Canadian family physician Medecin de famille canadien
Albuminuria
downin reviews1
1 study
Albuminuria
downin reviews1
Angiotensin-converting enzyme inhibitors decrease albuminuria (diabetic kidney disease).
“angiotensin convertase enzyme inhibitors and angiotensin receptor blockers alongside nonpharmacological measures have been the pillars of DKD treatment and reduction of albuminuria for many decades”
Reviewdiabetic kidney diseasekidney
Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives
Kidney & blood pressure research
eGFR
upin humans1
1 study
eGFR
upin humans1
Angiotensin-converting enzyme inhibitors increase eGFR in humans (Stage 1 hypertension) (mean increase of 5.6+/- 1.8 mL/min/1.73 m 2).
“the eGFR increased by the largest percentage in group A (ACE inhibitors; mean increase of 5.6+/- 1.8 mL/min/1.73 m 2).”
Human trialStage 1 hypertension12 weeks
Journal of pharmacy & bioallied sciences
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Angiotensin-converting enzyme inhibitors decrease systolic blood pressure in humans (Stage 1 hypertension) (mean decrease of 16.4+/- 3.2 mmHg).
“The SBP was reduced by the largest percentage in group A (ACE inhibitors; mean decrease of 16.4+/- 3.2 mmHg)”
Human trialStage 1 hypertension12 weeks
Journal of pharmacy & bioallied sciences
Systolic blood pressure
upin humans1
1 study
Systolic blood pressure
upin humans1
Angiotensin-converting enzyme inhibitors increase systolic blood pressure in humans (hypertension with comorbidities) (p<0.001).
“worsened the anthropometric profile, and SBP (p<0.001)”
Human trialhypertension with comorbidities2 years
Experimental gerontology
Physical function
downin humans1
1 study
Physical function
downin humans1
Angiotensin-converting enzyme inhibitors impair physical function in humans (hypertension with comorbidities) (p<0.05).
“The ACEi group reduced the upper body strength, upper and lower body flexibility and aerobic endurance (p<0.05)”
Human trialhypertension with comorbidities2 years
Experimental gerontology
All 34Fewer
What is angiotensin-converting enzyme inhibitors linked with?
28Studies link angiotensin-converting enzyme inhibitors with 28 measures, most often mortality (4 studies), dementia (3) and Alzheimer's disease (2).
Mortality
downin humans4HR 0.59–0.94
4 studies
Mortality
downin humans4HR 0.59–0.94
Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (compared with CCBs in participants with MASLD receiving monotherapy) (aHR 0.30, 95% CI 0.11-0.82).
“ACEIs and ARBs were associated with lower all-cause mortality compared with calcium channel blockers (CCBs, reference group; n = 47; 15 deaths) (ACEIs: adjusted hazard ratio [aHR], 0.30; 95% CI, 0.11-0.82”
Humanscompared with CCBs in participants with MASLD receiving monotherapyn = 458
Clinical and experimental hypertension (New York, N.Y. : 1993)
Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (target dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohort) (6% lower risk; HR 0.94, 95% CI 0.92-0.97).
“a 6% lower risk of death (HR, 0.94; 95% CI, 0.92-0.97)”
Humanstarget dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohorttarget dose5-yearn = 70,860
European journal of heart failure
Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (supratentorial primary malignant brain tumors) (HR 0.59, 95% CI 0.48-0.72).
“HR:0.71. 95% CI:0.59-0.86; HR:0.59, 95% CI:0.48-0.72; and HR:0.45, 95% CI:0.35-0.58 respectively”
Humanssupratentorial primary malignant brain tumorsn = 1,943
Neurological research
Angiotensin-converting enzyme inhibitors are linked with a lower risk of mortality in humans (proactive treatment).
“Proactive treatment with ACE-I/ARBs appeared to significantly reduce future mortality risk”
Humansproactive treatment
medRxivPreprint
Dementia
downin humans2upin humans1
3 studies
Dementia
downin humans2upin humans1
Angiotensin-converting enzyme inhibitors are linked with a higher risk of dementia in humans (baseline hypertension).
“whereas angiotensin-converting enzyme inhibitors (ACEIs) and diuretics increased risk.”
Humansbaseline hypertension
Antihypertensive medications and dementia in older adults with hypertension
medRxiv : the preprint server for health sciencesPreprint
Angiotensin-converting enzyme inhibitors are linked with a lower risk of dementia in people living with HIV.
“The results reveal a statistically significant reduction in dementia diagnosis for PLWH exposed to BBB-penetrant ACEi.”
Humansin people living with HIV
medRxiv : the preprint server for health sciencesPreprint
Angiotensin-converting enzyme inhibitors lower the risk of dementia in humans (older adults).
“In addition, some results found that ACEi and ARB users present delayed cognitive decline and reduced risk of dementia.”
Reviewolder adults
Frontiers in aging
Alzheimer's disease
upin humans1downin humans1HR 1.23
2 studies
Alzheimer's disease
upin humans1downin humans1HR 1.23
Angiotensin-converting enzyme inhibitors are associated with Alzheimer's disease in humans (Regular users compared with angiotensin receptor blocker users in UK Biobank) (HR 1.23, 95% CI 1.00–1.50).
“a higher incidence (hazard ratio, 1.23 [95% CI, 1.00-1.50]) of AD among regular users of angiotensin-converting enzyme inhibitors”
HumansRegular users compared with angiotensin receptor blocker users in UK Biobank
Genetic analysis links a blood enzyme to Alzheimer’s risk
Journal of the American Heart Association
Angiotensin-converting enzyme inhibitors are linked with a lower risk of Alzheimer's disease in humans (monotherapy vs calcium channel blockers in older adults with hypertension) (OR 0.36, 95 % CI 0.13-0.99).
“those who used angiotensin-converting enzyme inhibitors (ACEIs) had significantly lower odds of developing AD compared to those who used CCBs (OR 0.36, 95 % CI 0.13-0.99).”
Humansmonotherapy vs calcium channel blockers in older adults with hypertensionn = 539
Drugs & aging
COVID-19
downin humans2HR 0.78
2 studies
COVID-19
downin humans2HR 0.78
Angiotensin-converting enzyme inhibitors are linked with a lower risk of COVID-19 in humans (multivariable-adjusted) (HR: 0.78; 95% CI: 0.61-1.00).
“taking angiotensin-converting-enzyme inhibitors (HR: 0.78; 95% CI: 0.61-1.00), angiotensin-receptor-blockers (HR: 0.70; 95%CI: 0.51-0.96) and statins (HR: 0.75; 95% CI: 0.58-0.96) were associated with reduced risk.”
Humansmultivariable-adjustedn = 79,083
Medicina clinica (English ed.)
Angiotensin-converting enzyme inhibitors are linked with a lower risk of COVID-19 in humans (current use compared with never use; diagnosis outcome).
“current users of ACEI, ARB, statins, warfarin, direct factor Xa inhibitors and P2Y12 inhibitors were associated with reduced risks, compared to never users”
Humanscurrent use compared with never use; diagnosis outcome
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
PloS one
Range of motion
downin humans1
1 study
Range of motion
downin humans1
Angiotensin-converting enzyme inhibitors are associated with range of motion in humans after arthroscopic rotator cuff repair.
“ACEI use correlated with worse ROM and patient-reported outcomes, while statins again showed no effect.”
Reviewafter arthroscopic rotator cuff repairshoulder
The Journal of the American Academy of Orthopaedic Surgeons
Cognitive impairment
upin humans1
1 study
Cognitive impairment
upin humans1
Angiotensin-converting enzyme inhibitors are associated with cognitive impairment in humans (receiving antihypertensive therapy).
“Conversely, selective beta-blockers and angiotensin-converting enzyme (ACE) inhibitors were associated with an increased probability of impairment.”
Humansreceiving antihypertensive therapyn = 28,057
Frontiers in pharmacology
Vascular dementia
upin silico1OR 1.12
1 study
Vascular dementia
upin silico1OR 1.12
Angiotensin-converting enzyme inhibitors raise the risk of vascular dementia in silico (Mendelian randomization) (OR 1.12, 95% CI 1.01-1.24).
“Angiotensin-converting enzyme inhibition suggested increased VaD risk (OR = 1.12, 95% CI = 1.01-1.24).”
In silicoMendelian randomization
Nature aging
Myocardial infarction
downin humans1RR 0.65
1 study
Myocardial infarction
downin humans1RR 0.65
Angiotensin-converting enzyme inhibitors lower the risk of myocardial infarction in humans (compared with placebo) (RR 0.65; 95% CI 0.51-0.82).
“ACEIs were more effective in reducing myocardial infarction (RR 0.65; 95% CI 0.51-0.82)”
Reviewcompared with placebo
Drugs
Kidney failure
downin humans1HR 0.82
1 study
Kidney failure
downin humans1HR 0.82
Angiotensin-converting enzyme inhibitors are linked with a lower risk of kidney failure in humans (target dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohort) (18% lower risk; HR 0.82, 95% CI 0.75-0.89).
“In the ACEI cohort, target-dose was associated with a 18% lower risk of KF (HR, 0.82; 95% CI, 0.75-0.89)”
Humanstarget dose versus below-target dose, veterans with HFrEF, propensity-matched ACEI cohorttarget dose5-yearn = 70,860
European journal of heart failure
Cardiovascular death, myocardial infarction, stroke, and renal failure
downin humans1RR 0.87
1 study
Cardiovascular death, myocardial infarction, stroke, and renal failure
downin humans1RR 0.87
Angiotensin-converting enzyme inhibitors lower the risk of cardiovascular death, myocardial infarction, stroke, and renal failure in humans (compared to control in type 2 diabetes mellitus) (RR = 0.87, 95% CI = 0.81-0.94).
“In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control.”
Reviewcompared to control in type 2 diabetes mellitus
Cureus
All 28Fewer
Funding
1 grant since 2020National Institute on Aging$772K
Latest
79 papers in 12 monthsClinical Profiles and Guideline-Directed Therapy Patterns in Heart Failure With Preserved Versus Reduced Ejection Fraction: A Single-Center Retrospective Cohort Study From Pakistan
Adoption of ESC Guideline-Directed Heart Failure Pharmacotherapy and Outcomes: A Nationwide Claims-Based Cohort Study
Remote Algorithmic Uptitration of Guideline Directed Medical Therapy Improves Implementation and Patient Outcomes
Quadruple GDMT Reduces 30-Day Heart Failure Readmission in Real-World: SGLT2i Underutilisation Drives the Implementation Gap
Left Ventricular Mass Regression with Antihypertensive Therapy: A Systematic Review and Meta-Analysis of Cardiac Magnetic Resonance Studies
Angiotensinogen as a Risk Enhancer for Severe Hypertension: Sex-Specific Thresholds
Impact of ARBs plus beta-blockers and other antihypertensives on cognitive impairment: a longitudinal study
Persistence of guideline-directed medical therapy after heart failure hospitalisation in older adults with cancer
Achievement of secondary prevention targets after STEMI: results from the IMPACS Study
See all 197 papers on angiotensin-converting enzyme inhibitors